The relationship betweenUGT1A1gene & various diseases and prevention strategies / Dan Liu, Qi Yu, Qing Ning, Zhongqiu Liu, Jie Song
Abstract UDP-glucuronyltransferase 1A1 (UGT1A1) is a member of the Phase II metabolic enzyme family and the only enzyme that can metabolize detoxified bilirubin. Inactivation and very low activity of UGT1A1 in the liver can be fatal or lead to lifelong Gilbert’s syndrome (GS) and Crigler–Najjar syndrome (CN). To date, more than one hundred UGT1A1 polymorphisms have been discovered. Although most UGT1A1 polymorphisms are not fatal, which diseases might be associated with low activity UGT1A1 or UGT1A1 polymorphisms? This scientific topic has been studied for more than a hundred years, there are still many uncertainties. Herein, this article will summarize all the possibilities of UGT1A1 gene-related diseases, including GS and CN, neurological disease, hepatobiliary disease, metabolic difficulties, gallstone, cardiovascular disease, Crohn’s disease (CD) obesity, diabetes, myelosuppression, leukemia, tumorigenesis, etc., and provide guidance for researchers to conduct in-depth study on UGT1A1 gene-related diseases. In addition, this article not only summarizes the prevention strategies of UGT1A1 gene-related diseases, but also puts forward some insights for sharing.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Drug metabolism reviews - 54(2022), 1, Seite 1-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Dan [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Crigler–Najjar syndrome |
|---|
| Umfang: |
1 Online-Ressource (21 p) |
|---|
| doi: |
10.1080/03602532.2021.2001493 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011123273 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011123273 | ||
| 003 | DE-627 | ||
| 005 | 20230713210812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03602532.2021.2001493 |2 doi | |
| 035 | |a (DE-627)KFL011123273 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/03602532.2021.2001493 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Liu, Dan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The relationship betweenUGT1A1gene & various diseases and prevention strategies |c Dan Liu, Qi Yu, Qing Ning, Zhongqiu Liu, Jie Song |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (21 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract UDP-glucuronyltransferase 1A1 (UGT1A1) is a member of the Phase II metabolic enzyme family and the only enzyme that can metabolize detoxified bilirubin. Inactivation and very low activity of UGT1A1 in the liver can be fatal or lead to lifelong Gilbert’s syndrome (GS) and Crigler–Najjar syndrome (CN). To date, more than one hundred UGT1A1 polymorphisms have been discovered. Although most UGT1A1 polymorphisms are not fatal, which diseases might be associated with low activity UGT1A1 or UGT1A1 polymorphisms? This scientific topic has been studied for more than a hundred years, there are still many uncertainties. Herein, this article will summarize all the possibilities of UGT1A1 gene-related diseases, including GS and CN, neurological disease, hepatobiliary disease, metabolic difficulties, gallstone, cardiovascular disease, Crohn’s disease (CD) obesity, diabetes, myelosuppression, leukemia, tumorigenesis, etc., and provide guidance for researchers to conduct in-depth study on UGT1A1 gene-related diseases. In addition, this article not only summarizes the prevention strategies of UGT1A1 gene-related diseases, but also puts forward some insights for sharing | ||
| 653 | |a UGT1A1 | ||
| 653 | |a Gilbert’s syndrome | ||
| 653 | |a Crigler–Najjar syndrome | ||
| 653 | |a neurological disease | ||
| 653 | |a hepatobiliary disease | ||
| 653 | |a tumorigenesis | ||
| 700 | 1 | |a Yu, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Ning, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhongqiu |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Jie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism reviews |d Abingdon : Taylor & Francis Group, 1972 |g 54(2022), 1, Seite 1-21 |h Online-Ressource |w (DE-627)KFL000006025 |w (DE-600)2028205-9 |w (DE-576)27387960X |x 1097-9883 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2022 |g number:1 |g pages:1-21 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/03602532.2021.2001493 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_05 | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2022 |e 1 |h 1-21 | ||